

## EDITORIAL COMMENT

# Myocardial Viability

## Dead or Alive Is Not the Question!\*

Eike Nagel, MD, PhD, Andreas Schuster, MD

London, United Kingdom

When talking about viability—or better: hibernating myocardium—the question is not: “dead or alive,” the question is rather “what needs to be done to improve the patient’s symptoms and prognosis.” Little is known to answer this question.

The difficulties start with the definition of hibernating myocardium as “a state of myocardial hypocontractility during chronic hypoperfusion, in the presence of completely viable myocardium which recovers functionally upon revascularization.” This

[See page 494](#)

definition is problematic in the clinical setting because it is not entirely clear how we exactly define myocardial hypocontractility, how we define hypoperfusion (especially given that there is perfusion contraction matching), how we define functional recovery, and most important for a clinical test, how can we predict functional recovery?

The next level of complexity is the question of what is most important for the prognosis of the patient: left ventricular volumes and function, presence and extent of myocardial infarction, presence

and extent of hibernating myocardium, presence and extent of myocardial ischemia, or a combination of some or all of the parameters mentioned?

There are several things we know:

1. End-diastolic volume (EDV) and ejection fraction (EF) are strong parameters of outcome in a large variety of patient groups (1–3).
2. The presence and extent of myocardial infarction are strong parameters of outcome and seem to be superior to EDV and EF in a large variety of patient groups (4,5).
3. The presence of large amounts of myocardial ischemia is a strong predictor of negative outcome (6).

However, we do not know:

1. Whether the presence of viable myocardium is relevant to predict outcome.
2. Whether areas of peri-infarct ischemia are relevant.
3. Whether improvement of function after revascularization reduces the patient’s risk for subsequent events.
4. Which test/parameter to use to define hibernating myocardium.

The recent imaging substudy of the prospective multicenter outcome STICH (Surgical Treatment for Ischemic Heart Failure) trial can be used as an example to highlight these difficulties (7). Hibernating myocardium was assessed in 601 patients with ischemic cardiomyopathy (EF <35%) with single-photon emission computed tomography (SPECT) or dobutamine stress echocardiography (DSE). Two hundred ninety-eight patients received medical therapy and coronary artery bypass grafting, and 303 were randomized to optimal medical therapy alone. There was no association of hibernating

\*Editorials published in *JACC: Cardiovascular Imaging* reflect the views of the authors and do not necessarily represent the views of *JACC: Cardiovascular Imaging* or the American College of Cardiology.

From the Division of Imaging Sciences and Biomedical Engineering, King’s College London British Heart Foundation Centre of Excellence, National Institute of Health Research Biomedical Research Centre at Guy’s and St. Thomas’ NHS Foundation Trust, Wellcome Trust and Engineering and Physical Sciences Research Council Medical Engineering Centre, The Rayne Institute, St. Thomas’ Hospital, London, United Kingdom. The authors acknowledge grant support from the British Heart Foundation (BHF) (RE/08/003 and FS/10/029/28253) and the Biomedical Research Centre (BRC-CTF 196). Dr. Nagel has received significant grant support from Bayer Schering Pharma and Philips Healthcare. Dr. Schuster has reported that he has no relationships relevant to the contents of this paper to disclose.


myocardium and outcome in all patients and, importantly, no differences in prognosis, irrespective of whether patients with significant amounts of hibernating myocardium were revascularized or received medical therapy only. Considering the unknown variables mentioned in the previous text, it is important to note that the amount of myocardium required to classify the patients as having significant amounts of hibernating myocardium were different for SPECT and DSE and more than usually used in clinical practice. With SPECT, 65% of the myocardium had to be hibernating ( $\geq 11$  segments), and with DSE, 31% of the myocardium ( $\geq 5$  segments). In addition, the study considered the presence of hibernating tissue, irrespective of whether it was subtended by a diseased coronary artery or not. Furthermore, we need to acknowledge that SPECT and DSE may not represent the optimal investigation for hibernating myocardium because they have inherent technical limitations, such as a lower resolution and lower sensitivity of SPECT to detect subendocardial scarring in comparison to cardiac magnetic resonance (CMR) (8), as well as limited

endocardial border definition and acoustic windows for DSE. The fact that different noninvasive investigations provide information on different aspects of the pathophysiology (metabolism, scar, contractile reserve) consequently leads to results that may depend on the chosen imaging test (9). Indeed, previous meta-analyses have demonstrated the feasibility of noninvasive testing to guide revascularization when including positron emission tomography and CMR (10,11). Even though there is less evidence, the importance of an additional ischemic component to the presence of hibernating myocardium in patients with ischemic cardiomyopathy is increasingly recognized (12).

CMR has several options to characterize patients with suspected hibernating myocardium (13). It is the established reference standard to measure global left ventricular volumes and function (14), and it is optimally suited to assess regional wall thickness and motion (15). This is further advanced by using dobutamine stress testing and assessing quantitative parameters such as strain, for example, with tagging (16) or feature tracking (17). In addition, the amount of late gadolinium enhanced (LGE) tissue represents scar with unprecedented accuracy (18,19). Viable tissue is then defined as dysfunctional myocardium without scar.

In this issue of *JACC*, Romero et al. (20) provide a meta-analysis of the value of 3 different diagnostic strategies with CMR to predict functional recovery after revascularization. Hibernating tissue is defined as a segment: 1) of end-diastolic wall thickness of  $<5.5$  to  $6$  mm; 2) with a wall motion abnormality at rest, but  $<50\%$  transmural scar; or 3) that demonstrates functional recruitment (contractile reserve) during low-dose dobutamine stress. They also tested other cutoffs for LGE as well as a combination of LGE with low-dose dobutamine stress. The major findings are:

1. LGE with a cutoff value of 50% transmural scar yields the highest sensitivity and negative predictive value (NPV). Using a higher or a lower cutoff value for the definition of hibernation can increase either sensitivity (with reduced specificity) or specificity (with reduced sensitivity). However, the strongest differentiation between improvement and nonimprovement is reached with the standard cutoff used by most authors and recommended in the guidelines (21).
2. Low-dose dobutamine yields the highest overall accuracy and the best specificity and positive predictive value (PPV).



**Figure 1. Algorithm to Assess Hibernating Myocardium With CMR**

In the presence of wall motion abnormalities at rest in segments subtended by a diseased coronary artery, scar imaging serves as a first-line test. In the absence of scar (likelihood of functional recovery  $\sim 78\%$  [19]) and in the presence of scar with a transmural scar of  $>50\%$  (likelihood of functional recovery  $\sim 8\%$  [19]), late gadolinium enhancement (LGE) is sufficient to predict functional recovery. In the presence of scars with a transmural scar of 1% to 50% (likelihood of functional recovery  $\sim 53\%$  [19]), low-dose dobutamine stress magnetic resonance (LDDSMR) testing allows for the assessment of contractile reserve, which guides further management. CMR = cardiac magnetic resonance.

Download English Version:

<https://daneshyari.com/en/article/2938439>

Download Persian Version:

<https://daneshyari.com/article/2938439>

[Daneshyari.com](https://daneshyari.com)